Veradermics, Inc(MANE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MANE Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Veradermics, Inc (MANE), a Healthcare sector company. MANE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Veradermics, Inc reports net income of $-27.2M, free cash flow of $-21.2M. Top institutional holders of MANE by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, SR ONE CAPITAL MANAGEMENT,, CITADEL ADVISORS, based on the most recent SEC filings. MANE trades on the NYSE exchange and files with the SEC under CIK 1827635. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MANE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Veradermics, Inc directly from SEC EDGAR.
Net Income
Q1 2026
$-27.2M
Free Cash Flow
Q1 2026
$-21.2M
ROIC
Q1 2026
-7.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
Operating Income
EPS (Diluted)
Total Assets
Op. Cash Flow
| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Net Income | $-26.5M | — |
| Operating Income | $-26.8M | — |
| EPS (Diluted) | $-37.05 | — |
| Total Assets | $55.5M | — |
| Operating Cash Flow | $-23.7M | — |
AI Insight: MANE Financial Trends
Veradermics swung to Q1 2026 losses across all profitability metrics; equity recovered sharply but cash burn demands scrutiny.
• Operating income fell to -$30M in Q1 2026; net income also negative at -$27M.
• Operating cash flow turned negative at -$21M in Q1 2026, indicating cash consumption.
• Stockholders' equity rebounded to $391M in Q1 2026 from -$121M deficit in Q4 2025.
⚠ Negative operating cash flow in Q1 2026 — sustainability of equity recovery depends on returning to positive cash generation.
⚠ Revenue data unavailable; cannot assess top-line trajectory or margin performance drivers.
AI Insight: MANE Ratio Trends
Veradermics swung to significant losses in Q1 2026, with ROE, ROA, and ROIC all deeply negative.
• Q1 2026 net income turned sharply negative: ROE fell to -27.9%, ROA to -27.4%, and ROIC to -30.6%.
⚠ No operating or net margin data available; unable to assess profitability path or operational efficiency.
⚠ Debt-to-equity ratio absent; leverage position unclear amid negative returns.
Get alerted when MANE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Veradermics, Inc including:
Top Institutional Holders of MANE
SUVRETTA CAPITAL MANAGEMENT, LLC
$263.3M4,168,970 shSR ONE CAPITAL MANAGEMENT, LP
$151.7M2,401,868 shCITADEL ADVISORS LLC
$115.3M1,825,672 shFMR LLC
$113.2M1,792,909 shVIKING GLOBAL INVESTORS LP
$106.8M1,690,555 shSiren, L.L.C.
$95.1M1,505,374 shADAGE CAPITAL PARTNERS GP, L.L.C.
$69.5M1,100,000 shabrdn plc
$66.6M1,054,660 shINFINITUM ASSET MANAGEMENT, LLC
$46.2M731,149 shVANGUARD CAPITAL MANAGEMENT LLC
$44.2M699,645 sh
| Fund | Value | Shares |
|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $263.3M | 4,168,970 |
| SR ONE CAPITAL MANAGEMENT, LP | $151.7M | 2,401,868 |
| CITADEL ADVISORS LLC | $115.3M | 1,825,672 |
| FMR LLC | $113.2M | 1,792,909 |
| VIKING GLOBAL INVESTORS LP | $106.8M | 1,690,555 |
| Siren, L.L.C. | $95.1M | 1,505,374 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $69.5M | 1,100,000 |
| abrdn plc | $66.6M | 1,054,660 |
| INFINITUM ASSET MANAGEMENT, LLC | $46.2M | 731,149 |
| VANGUARD CAPITAL MANAGEMENT LLC | $44.2M | 699,645 |
More Healthcare Companies
View all Healthcare →Put MANE on your watchlist
Track score changes the day Veradermics, Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MANE a good stock to buy?
13F Pro's AI-powered analysis of Veradermics, Inc (MANE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MANE are available on the MANE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MANE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MANE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Veradermics, Inc's investment landscape.